A Safety and Preliminary Efficacy Study of SBT6290 Alone and in Combination With PD-(L)1 Inhibitors in Select Advanced Solid Tumors

NCT05234606 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

WITHDRAWN

Status

INDUSTRY

Sponsor class

Stopped Sponsor decision based on strategic re-alignment

Conditions

Urothelial Carcinoma
Triple Negative Breast Cancer
Non-small Cell Lung Cancer
Squamous Cell Carcinoma of Head and Neck
Hormone Receptor-positive/HER2-negative Breast Cancer

Interventions

DRUG: SBT6290
DRUG: SBT6290
DRUG: pembrolizumab

Sponsor

Silverback Therapeutics